Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) EBT (2016 - 2025)

CytomX Therapeutics' EBT history spans 12 years, with the latest figure at -$26.5 million for Q4 2025.

  • For Q4 2025, EBT fell 239.7% year-over-year to -$26.5 million; the TTM value through Dec 2025 reached -$17.1 million, down 153.38%, while the annual FY2025 figure was -$17.1 million, 153.38% down from the prior year.
  • EBT reached -$26.5 million in Q4 2025 per CTMX's latest filing, down from -$14.2 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $23.6 million in Q1 2025 to a low of -$34.8 million in Q4 2021.
  • Average EBT over 5 years is -$9.8 million, with a median of -$7.6 million recorded in 2022.
  • The largest YoY upside for EBT was 893.6% in 2024 against a maximum downside of 496.41% in 2024.
  • A 5-year view of EBT shows it stood at -$34.8 million in 2021, then skyrocketed by 74.8% to -$8.8 million in 2022, then skyrocketed by 121.72% to $1.9 million in 2023, then surged by 893.6% to $18.9 million in 2024, then tumbled by 239.7% to -$26.5 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's EBT are -$26.5 million (Q4 2025), -$14.2 million (Q3 2025), and -$91000.0 (Q2 2025).